A defective flexible loop contributes to the processing and gating defects of the predominant cystic fibrosis‐causing mutation

People with the genetic disease cystic fibrosis (CF) often carry a deletion mutation ∆F508 on the gene encoding the CF transmembrane conductance regulator (CFTR) Cl− channel. This mutation greatly reduces the CFTR maturation process and slows the channel opening rate. Here, we investigate whether residues near F508 contribute to these defects in ∆F508‐CFTR. Most deletion mutations, but not alanine substitutions, of individual residues from positions 503 to 513 impaired CFTR maturation. Interestingly, only protein processing of ∆Y512‐CFTR, like that of ∆F508‐CFTR, was greatly improved by low‐temperature culture at 27°C or small‐molecule corrector C18. The 2 mutant Cl− channels were equally slow to open, suggesting that they may share common structural flaws. Studies on the H3‐H4 loop that links residues F508 and Y512 demonstrate that G509A/V510G mutations, moving G5091 position backward in the loop, markedly enhanced ∆F508‐CFTR maturation and opening rate while promoting protein stability and persistence of the H3 helix in ∆F508 nucleotide‐binding domain 1. Moreover, V510A/S511A mutations noticeably increased ∆Y512‐CFTR maturation at 27°C and its opening rate. Thus, loop abnormalities may contribute to ∆F508‐ and ∆Y512‐CFTR defects. Importantly, correcting defects from G509 displacement in ∆F508‐CFTR may offer a new avenue for drug discovery and CF treatments.—Chen, X., Zhu, S., Zhenin, M., Xu, W., Bose, S. J., Wong, M. P.‐F., Leung, G. P. H., Senderowitz, H., Chen, J.‐H. A defective flexible loop contributes to the processing and gating defects of the predominant cystic fibrosis‐causing mutation. FASEB J. 33, 5126–5142 (2019). www.fasebj.org

[1]  Nikhil T. Awatade,et al.  R560S: A class II CFTR mutation that is not rescued by current modulators. , 2019, Journal of Cystic Fibrosis.

[2]  Nikhil T. Awatade,et al.  Partial rescue of F508del‐cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual‐acting small molecule , 2018, British journal of pharmacology.

[3]  S. Rowe,et al.  Toward inclusive therapy with CFTR modulators: Progress and challenges , 2017, Pediatric pulmonology.

[4]  Jue Chen,et al.  Conformational Changes of CFTR upon Phosphorylation and ATP Binding , 2017, Cell.

[5]  D. Clarke,et al.  Corrector VX‐809 promotes interactions between cytoplasmic loop one and the first nucleotide‐binding domain of CFTR , 2017, Biochemical pharmacology.

[6]  V. Vauthier,et al.  Targeted pharmacotherapies for defective ABC transporters , 2017, Biochemical pharmacology.

[7]  R. Mahalakshmi,et al.  Metamorphic Proteins: Emergence of Dual Protein Folds from One Primary Sequence. , 2017, Biochemistry.

[8]  D. Gadsby,et al.  Molecular Structure of the Human CFTR Ion Channel , 2017, Cell.

[9]  D. Sheppard,et al.  Altering intracellular pH reveals the kinetic basis of intraburst gating in the CFTR Cl− channel , 2017, The Journal of physiology.

[10]  R. Ford,et al.  Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation* , 2017, The Journal of Biological Chemistry.

[11]  Jue Chen,et al.  Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator , 2016, Cell.

[12]  I. Sabirzhanova,et al.  Correctors Rescue CFTR Mutations in Nucleotide‐Binding Domain 1 (NBD1) by Modulating Proteostasis , 2016, Chembiochem : a European journal of chemical biology.

[13]  R. Nussinov,et al.  The Role of Protein Loops and Linkers in Conformational Dynamics and Allostery. , 2016, Chemical reviews.

[14]  Hanoch Senderowitz,et al.  REMD Simulations Reveal the Dynamic Profile and Mechanism of Action of Deleterious, Rescuing, and Stabilizing Perturbations to NBD1 from CFTR , 2015, J. Chem. Inf. Model..

[15]  J. Riordan,et al.  Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly. , 2015, Journal of Molecular Biology.

[16]  A. Toye,et al.  CFTR potentiators partially restore channel function to A561E‐CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del‐CFTR , 2014, British Journal of Pharmacology.

[17]  M. Amaral,et al.  Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D‐CFTR , 2014, The Journal of physiology.

[18]  Piotr Zielenkiewicz,et al.  Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain , 2013, EMBO molecular medicine.

[19]  Sadis Matalon,et al.  The silent codon change I507‐ATC→ATT contributes to the severity of the ΔF508 CFTR channel dysfunction , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  M. Amaral,et al.  Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. , 2013, Current pharmaceutical design.

[21]  G. Lukács,et al.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.

[22]  T. Hwang,et al.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle , 2013, Proceedings of the National Academy of Sciences.

[23]  Xuehong Liu,et al.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity. , 2012, Biochemistry.

[24]  Pradeep Kota,et al.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. , 2012, Journal of molecular biology.

[25]  K. Du,et al.  Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.

[26]  Philip J. Thomas,et al.  Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.

[27]  M. Welsh,et al.  Human–mouse cystic fibrosis transmembrane conductance regulator (CFTR) chimeras identify regions that partially rescue CFTR-ΔF508 processing and alter its gating defect , 2011, Proceedings of the National Academy of Sciences.

[28]  K. Kirk,et al.  Thermally Unstable Gating of the Most Common Cystic Fibrosis Mutant Channel (ΔF508) , 2011, The Journal of Biological Chemistry.

[29]  A. Mehta,et al.  Contribution of Casein Kinase 2 and Spleen Tyrosine Kinase to CFTR Trafficking and Protein Kinase A-Induced Activity , 2011, Molecular and Cellular Biology.

[30]  S. Richter,et al.  The ΔF508 Mutation Causes CFTR Misprocessing and Cystic Fibrosis–Like Disease in Pigs , 2011, Science Translational Medicine.

[31]  Philip J. Thomas,et al.  The Primary Folding Defect and Rescue of ΔF508 CFTR Emerge during Translation of the Mutant Domain , 2010, PloS one.

[32]  M. Welsh Targeting the basic defect in cystic fibrosis. , 2010, New England Journal of Medicine.

[33]  Efrat Ben-Zeev,et al.  Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening , 2010, J. Comput. Aided Mol. Des..

[34]  Zhengrong Yang,et al.  Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1 , 2010, Protein science : a publication of the Protein Society.

[35]  Zhengrong Yang,et al.  Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis , 2010, Protein science : a publication of the Protein Society.

[36]  Pradeep Kota,et al.  Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. , 2010, Journal of molecular biology.

[37]  Jason C. Young,et al.  Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane , 2010, Science.

[38]  Kenneth L. Nesbitt,et al.  Restoration of domain folding and interdomain assembly by second‐site suppressors of the ΔF508 mutation in CFTR , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  H. Senderowitz,et al.  The Cystic Fibrosis-causing Mutation ΔF508 Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis* , 2010, The Journal of Biological Chemistry.

[40]  D. Clarke,et al.  The V510D Suppressor Mutation Stabilizes ΔF508-CFTR at the Cell Surface† , 2010, Biochemistry.

[41]  John F Hunt,et al.  Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. , 2010, Protein engineering, design & selection : PEDS.

[42]  J. M. Sauder,et al.  Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. , 2010, Journal of molecular biology.

[43]  Julie D Forman-Kay,et al.  NMR evidence for differential phosphorylation‐dependent interactions in WT and ΔF508 CFTR , 2010, The EMBO journal.

[44]  D. Cyr,et al.  Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. , 2008, Molecular biology of the cell.

[45]  Adrian W. R. Serohijos,et al.  Phenylalanine-508 mediates a cytoplasmic–membrane domain contact in the CFTR 3D structure crucial to assembly and channel function , 2008, Proceedings of the National Academy of Sciences.

[46]  Nikolay V. Dokholyan,et al.  Diminished Self-Chaperoning Activity of the ΔF508 Mutant of CFTR Results in Protein Misfolding , 2008, PLoS Comput. Biol..

[47]  M. Amaral,et al.  Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. , 2008, Chemistry & biology.

[48]  M. Welsh,et al.  Processing and function of CFTR-ΔF508 are species-dependent , 2007, Proceedings of the National Academy of Sciences.

[49]  C. Soares,et al.  Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms , 2006, Proceedings of the National Academy of Sciences.

[50]  Kai Du,et al.  Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. , 2005, The Journal of clinical investigation.

[51]  J. M. Sauder,et al.  Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.

[52]  J. M. Sauder,et al.  Structure of nucleotide‐binding domain 1 of the cystic fibrosis transmembrane conductance regulator , 2004, The EMBO journal.

[53]  L. Gansheroff,et al.  Mutations in the Nucleotide Binding Domain 1 Signature Motif Region Rescue Processing and Functional Defects of Cystic Fibrosis Transmembrane Conductance Regulator ΔF508* , 2002, The Journal of Biological Chemistry.

[54]  D. Sheppard,et al.  Phloxine B Interacts with the Cystic Fibrosis Transmembrane Conductance Regulator at Multiple Sites to Modulate Channel Activity* 210 , 2002, The Journal of Biological Chemistry.

[55]  Fei Wang,et al.  Deletion of phenylalanine 508 causes attenuated phosphorylation‐dependent activation of CFTR chloride channels , 2000, The Journal of physiology.

[56]  J. Riordan,et al.  Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. , 1999, Molecular cell.

[57]  K. Kirk,et al.  Activation of ΔF508 CFTR in an epithelial monolayer. , 1998, American journal of physiology. Cell physiology.

[58]  T. Hwang,et al.  Genistein potentiates wild-type and delta F508-CFTR channel activity. , 1997, The American journal of physiology.

[59]  P. Thomas,et al.  Alteration of the Cystic Fibrosis Transmembrane Conductance Regulator Folding Pathway , 1996, The Journal of Biological Chemistry.

[60]  M. Welsh,et al.  The Two Nucleotide-binding Domains of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Have Distinct Functions in Controlling Channel Activity (*) , 1995, The Journal of Biological Chemistry.

[61]  R. Frizzell,et al.  ATP alters current fluctuations of cystic fibrosis transmembrane conductance regulator: evidence for a three-state activation mechanism , 1994, The Journal of general physiology.

[62]  H. A. Berger,et al.  Identification of revertants for the cystic fibrosis ΔF508 mutation using STE6-CFTR chimeras in yeast , 1993, Cell.

[63]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[64]  P. Pedersen,et al.  The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. , 1992, The Journal of biological chemistry.

[65]  F. Collins,et al.  Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. , 1991, Science.

[66]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[67]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[68]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[69]  Kaye Walizer Defective , 2021, Encyclopedia of the UN Sustainable Development Goals.

[70]  N. Dokholyan,et al.  Correctors of F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2014 .

[71]  K. Kirk,et al.  The CFTR ion channel: gating, regulation, and anion permeation. , 2013, Cold Spring Harbor perspectives in medicine.

[72]  Paola Bisignano,et al.  Molecular dynamics analysis of the wild type and dF508 mutant structures of the human CFTR-nucleotide binding domain 1. , 2010, Biochimie.

[73]  M. Welsh,et al.  Processing and function of CFTR-DeltaF508 are species-dependent. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Chad A Brautigam,et al.  Side chain and backbone contributions of Phe508 to CFTR folding , 2005, Nature Structural &Molecular Biology.

[75]  Kai Du,et al.  The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.

[76]  L. Gansheroff,et al.  Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. , 2002, The Journal of biological chemistry.

[77]  M. Welsh,et al.  Mutation of R555 in CFTR-delta F508 enhances function and partially corrects defective processing. , 1996, Receptors & channels.

[78]  R. Crystal,et al.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. , 1991, Nature.